<!DOCTYPE html>
<html xmlns="http://www.w3.org/1999/xhtml" lang="" xml:lang="">
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <meta name="author" content="biyokea" />
  <meta name="dcterms.date" content="2025-10-13" />
<title>PCOS, transmascs &amp; testosterone</title>
<style>
    code{white-space: pre-wrap;}
    span.smallcaps{font-variant: small-caps;}
    div.columns{display: flex; gap: min(4vw, 1.5em);}
    div.column{flex: auto; overflow-x: auto;}
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
    /* The extra [class] is a hack that increases specificity enough to
       override a similar rule in reveal.js */
    ul.task-list[class]{list-style: none;}
    ul.task-list li input[type="checkbox"] {
      font-size: inherit;
      width: 0.8em;
      margin: 0 0.8em 0.2em -1.6em;
      vertical-align: middle;
    }
    .display.math{display: block; text-align: center; margin: 0.5rem auto;}
    /* CSS for citations */
    div.csl-bib-body { }
    div.csl-entry {
      clear: both;
      margin-bottom: 0em;
    }
    .hanging-indent div.csl-entry {
      margin-left:2em;
      text-indent:-2em;
    }
    div.csl-left-margin {
      min-width:2em;
      float:left;
    }
    div.csl-right-inline {
      margin-left:2em;
      padding-left:1em;
    }
    div.csl-indent {
      margin-left: 2em;
    }</style>
  <link rel="stylesheet" href="/css/index.css" />
  <link rel="stylesheet" href="https://fonts.cdnfonts.com/css/latin-modern-sans" />
  <script type="module" src="/js/citation.js"></script>
  <script type="module" src="/js/toc.js"></script>
  <link href="/feed.xml" type="application/atom+xml" rel="alternate" title="WHSAH Atom feed" />
</head>
<body>
<div id="navigation-container">
    <div id="navigation-options">
        <div class="nav-option"><a href="/">Home</a></div>
        <div class="nav-option"><a href="/about">About</a></div>
        <div class="nav-option">
            <details id="navigation-menu">
                <summary><b>Posts</b></summary>
                <nav>
                    <ul>
                        <li><a href="/posts/pcos-transmascs-and-testosterone">PCOS, transmascs & testosterone</a></li>
                        <li><a href="/posts/rethinking-progesterone-and-androgens">Rethinking Progesterone and Androgens</a></li>
                        <li><a href="/posts/english-translation-of-a-method-for-preparing-estradiol">English Translation of "A Method for Preparing Estradiol"</a></li>
                    </ul>
                </nav>
            </details>
        </div>
        <div class="nav-option feed">
            <a href="/feed.xml">Feed</a>
        </div>
    </div>
</div>
<script>
    const navigationMenu = document.getElementById('navigation-menu');
    document.addEventListener('mousedown', (e) => {
        const isClickOnSummary = e.target.closest('summary') !== null;
        if (navigationMenu?.open && !isClickOnSummary && !navigationMenu.contains(e.target)) {
            navigationMenu.open = false;
        }
    });
</script>
<div class="grid-area">
    <div class="content-area">
        <header id="title-block-header">
                        <h1 class="title">PCOS, transmascs &amp;
testosterone</h1>
                                                    By  biyokea   | published 2025-10-13  
                        <!--<p class="author">biyokea</p>
                            <p class="date">2025-10-13</p>
                -->
                            <div class="abstract">
                <div class="abstract-title"><h2>Abstract</h2></div>
                <p>Polycystic ovary syndrome (PCOS) is a common medical
                condition in cisgender women. Typically regarded as an
                hormonal/reproductive disorder, its metabolic dimension
                is often overlooked. Misunderstood and inadequately
                managed in cisgender women, PCOS is also prevalent in
                transmasculine individuals, whose treatment presents
                some unique challenges. Even in transmasculine
                individuals without PCOS, this topic is relevant as it
                leads to misconceptions and allows us to discuss issues
                related to scientific research in transgender health.
                This article provides an overview of PCOS-related
                aspects in hormonal transition and among transmasculine
                people: prevalence, the causal relationship between
                testosterone treatment and PCOS, and the impact of PCOS
                on testosterone therapy.</p>
                </div>
                    </header>
                <nav id="TOC" role="doc-toc">
        <h2>Contents</h2>
        <ul>
        <li><a href="#pcos-in-a-nutshell"
        id="toc-pcos-in-a-nutshell"><span
        class="toc-section-number">1</span> PCOS in a Nutshell</a></li>
        <li><a
        href="#overrepresentation-of-pcos-in-transmasculine-individuals-or-research-priorities"
        id="toc-overrepresentation-of-pcos-in-transmasculine-individuals-or-research-priorities"><span
        class="toc-section-number">2</span> Overrepresentation of PCOS
        in Transmasculine Individuals or Research Priorities?</a>
        <ul>
        <li><a
        href="#why-study-pcos-prevalence-in-transmasculine-people"
        id="toc-why-study-pcos-prevalence-in-transmasculine-people"><span
        class="toc-section-number">2.1</span> Why Study PCOS Prevalence
        in Transmasculine People?</a></li>
        <li><a href="#systematic-literature-review"
        id="toc-systematic-literature-review"><span
        class="toc-section-number">2.2</span> Systematic Literature
        Review</a></li>
        <li><a
        href="#what-these-results-reveal-about-research-priorities-in-transgender-health"
        id="toc-what-these-results-reveal-about-research-priorities-in-transgender-health"><span
        class="toc-section-number">2.3</span> What These Results Reveal
        About Research Priorities in Transgender Health</a></li>
        </ul></li>
        <li><a
        href="#does-testosterone-therapy-cause-pcos-in-transmasculine-individuals"
        id="toc-does-testosterone-therapy-cause-pcos-in-transmasculine-individuals"><span
        class="toc-section-number">3</span> Does Testosterone Therapy
        Cause PCOS in Transmasculine Individuals?</a>
        <ul>
        <li><a
        href="#metabolic-changes-evolution-towards-a-typical-male-profile-distinct-from-pcos"
        id="toc-metabolic-changes-evolution-towards-a-typical-male-profile-distinct-from-pcos"><span
        class="toc-section-number">3.1</span> Metabolic Changes:
        Evolution Towards a Typical Male Profile, Distinct from
        PCOS</a></li>
        <li><a
        href="#reproductive-system-modifications-sometimes-polycystic-ovaries-but-distinct-changes-from-pcos"
        id="toc-reproductive-system-modifications-sometimes-polycystic-ovaries-but-distinct-changes-from-pcos"><span
        class="toc-section-number">3.2</span> Reproductive System
        Modifications: Sometimes Polycystic Ovaries, but Distinct
        Changes from PCOS</a></li>
        <li><a
        href="#if-pcos-and-testosterone-therapy-are-unrelated-why-these-comparisons"
        id="toc-if-pcos-and-testosterone-therapy-are-unrelated-why-these-comparisons"><span
        class="toc-section-number">3.3</span> If PCOS and Testosterone
        Therapy Are Unrelated, Why These Comparisons?</a></li>
        </ul></li>
        <li><a
        href="#pcos-and-testosterone-therapy-a-rather-limited-impact"
        id="toc-pcos-and-testosterone-therapy-a-rather-limited-impact"><span
        class="toc-section-number">4</span> PCOS and Testosterone
        Therapy: A Rather Limited Impact</a>
        <ul>
        <li><a href="#general-considerations"
        id="toc-general-considerations"><span
        class="toc-section-number">4.1</span> General
        Considerations</a></li>
        <li><a
        href="#impact-on-health-a-critical-lack-of-information-but-reassuring-data"
        id="toc-impact-on-health-a-critical-lack-of-information-but-reassuring-data"><span
        class="toc-section-number">4.2</span> Impact on Health: A
        Critical Lack of Information but Reassuring Data</a></li>
        <li><a href="#fertility" id="toc-fertility"><span
        class="toc-section-number">4.3</span> Fertility</a></li>
        <li><a
        href="#in-practice-i-have-pcos-and-want-to-take-testosterone-what-should-i-do"
        id="toc-in-practice-i-have-pcos-and-want-to-take-testosterone-what-should-i-do"><span
        class="toc-section-number">4.4</span> In Practice: I Have PCOS
        and Want to Take Testosterone, What Should I Do?</a></li>
        </ul></li>
        <li><a href="#bibliography"
        id="toc-bibliography">Bibliography</a></li>
        </ul>
        </nav>
                            <div class="editors-box"><h2>
Editor’s Note
</h2>
<p>
This post is a translation of the article
<a href="https://hackmd.io/@biyokea/sopk_transmasc_testo" target="_blank">SOPK,
personnes transmasculines &amp; testostérone</a> originally in French.
</p>
<p>
Translation by alix and biyokea, with help from the
<a href="https://huggingface.co/CohereLabs/aya-expanse-32b" target="_blank">Aya-Expanse-32B</a>
multilingual open-weight LLM, run on local hardware.
</p></div>
                <h2 data-number="1" id="pcos-in-a-nutshell"><span
                class="header-section-number">1</span> PCOS in a
                Nutshell</h2>
                <p>From a diagnostic perspective, Polycystic Ovary
                Syndrome (PCOS) is defined by the presence of at least
                two of the following three criteria <span
                class="citation"
                data-cites="therotterdameshre/asrm-sponsoredpcosconsensusworkshopgroup_revised_2004">(<a
                href="#ref-therotterdameshre/asrm-sponsoredpcosconsensusworkshopgroup_revised_2004"
                role="doc-biblioref">The Rotterdam PCOS Consensus
                Workshop Group, 2004</a>)</span>:</p>
                <ul>
                <li><strong>Oligo-ovulation or anovulation</strong></li>
                <li><strong>Clinical and/or biological
                hyperandrogenism</strong></li>
                <li><strong>Polycystic ovarian morphology</strong></li>
                </ul>
                <p>Combinations of these criteria allow classification
                into four phenotypes:</p>
                <div class="table-container-shrink">
                <table>
                <thead>
                <tr>
                <th>Phenotype A</th>
                <th>Phenotype B</th>
                <th>Phenotype C</th>
                <th>Phenotype D</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                <td>hyperandrogenism</td>
                <td>hyperandrogenism</td>
                <td>hyperandrogenism</td>
                <td></td>
                </tr>
                <tr>
                <td>oligo-/anovulation</td>
                <td>oligo-/anovulation</td>
                <td></td>
                <td>oligo-/anovulation</td>
                </tr>
                <tr>
                <td>PCO morphology</td>
                <td></td>
                <td>PCO morphology</td>
                <td>PCO morphology</td>
                </tr>
                </tbody>
                </table>
                </div>
                <p>PCOS is also a diagnosis of exclusion, meaning that
                other possible causes must be ruled out first. These
                criteria are the most widely accepted, but they do not
                unanimously agree, either from a diagnostic or
                pathophysiological standpoint.</p>
                <p>Indeed, PCOS is a misnomer <span class="citation"
                data-cites="norman_tis_2023">(<a
                href="#ref-norman_tis_2023" role="doc-biblioref">Norman
                et al., 2023</a>)</span>: polycystic ovarian morphology
                is not an essential or even central element of PCOS.
                Conversely, <strong>clinical or biological
                hyperandrogenism</strong> appears to be an essential
                component of PCOS. Biological hyperandrogenism is the
                atypically high presence of androgens in women as
                measured in a blood test ; clinical hyperandrogenism
                refers to the visible effects of androgenic activity,
                like facial hair, in women, when they exceed what is
                considered typical for cisgender, non-intersex women.
                <strong>Insulin resistance</strong> is another
                fundamental aspect of PCOS from an endocrinometabolic
                perspective, yet severely underlooked. For more on this
                subject, see Unfer et al. <span class="citation"
                data-cites="unfer_when_2024">(<a
                href="#ref-unfer_when_2024"
                role="doc-biblioref">2024</a>)</span>.</p>
                <p>To summarize, it is important to understand that:</p>
                <ul>
                <li><strong>Polycystic ovarian morphology is not
                synonymous with PCOS</strong></li>
                <li><strong>Insulin resistance and metabolic
                disturbances are essential but often neglected aspects
                of PCOS</strong></li>
                </ul>
                <p>Lastly, while PCOS is classically defined only in
                women (and by extension, transmasculine individuals), a
                <strong>non-ovarian form of PCOS</strong> (“male PCOS”
                in cisgender men) characterized notably by the
                hyperandrogenic and metabolic aspects of classic PCOS,
                is beginning to be recognized in the scientific
                community <span class="citation"
                data-cites="diguardo_male_2020 mettawi_male_2024 lafci_pcos_2024">(<a
                href="#ref-diguardo_male_2020" role="doc-biblioref">Di
                Guardo et al., 2020</a>; <a href="#ref-lafci_pcos_2024"
                role="doc-biblioref">Lafci et al., 2024</a>; <a
                href="#ref-mettawi_male_2024"
                role="doc-biblioref">Mettawi, 2024</a>)</span>.
                <strong>Transfeminine individuals can also be affected
                by PCOS</strong>, although this falls outside the scope
                of this article.</p>
                <h2 data-number="2"
                id="overrepresentation-of-pcos-in-transmasculine-individuals-or-research-priorities"><span
                class="header-section-number">2</span>
                Overrepresentation of PCOS in Transmasculine Individuals
                or Research Priorities?</h2>
                <h3 data-number="2.1"
                id="why-study-pcos-prevalence-in-transmasculine-people"><span
                class="header-section-number">2.1</span> Why Study PCOS
                Prevalence in Transmasculine People?</h3>
                <p>In cisgender women, PCOS is common—although it is not
                always diagnosed. Prevalence varies widely depending on
                various factors, including the diagnostic criteria used,
                but estimates range from 10-13% <span class="citation"
                data-cites="therotterdameshre/asrm-sponsoredpcosconsensusworkshopgroup_revised_2004">(<a
                href="#ref-therotterdameshre/asrm-sponsoredpcosconsensusworkshopgroup_revised_2004"
                role="doc-biblioref">The Rotterdam PCOS Consensus
                Workshop Group, 2004</a>)</span> and reaching as high as
                20% in Europe and North America <span class="citation"
                data-cites="chiaffarino_prevalence_2022">(<a
                href="#ref-chiaffarino_prevalence_2022"
                role="doc-biblioref">Chiaffarino et al.,
                2022</a>)</span>.</p>
                <p>Though disputed today, for a long time it was
                believed that PCOS was more prevalent in trans men and
                transmasculine individuals than in cisgender women,
                particularly <strong>in the context of research into the
                etiologies of gender dysphoria</strong>: perhaps trans
                men are such because they were exposed to androgens
                prenatally, or maybe they have higher androgen levels
                than average, as is often the case in PCOS? These
                studies, <strong>aside from being deeply stigmatizing,
                pathologizing</strong>, and contradictory to values such
                as self-determination, are also simply inconclusive. For
                a critical review, see Levin et al. <span
                class="citation" data-cites="levin_biological_2023">(<a
                href="#ref-levin_biological_2023"
                role="doc-biblioref">2023</a>)</span>.</p>
                <p>This context is important to keep in mind when
                examining research on PCOS in transmasculine
                individuals, as it implies a research stance that, as
                always, is not neutral.</p>
                <h3 data-number="2.2"
                id="systematic-literature-review"><span
                class="header-section-number">2.2</span> Systematic
                Literature Review</h3>
                <p>This context explains the abundance of studies
                examining PCOS prevalence in transmasculine individuals.
                The author conducted a systematic literature review
                <span class="citation"
                data-cites="biyokea_prevalence_2025">(<a
                href="#ref-biyokea_prevalence_2025"
                role="doc-biblioref">biyokea, 2025</a>)</span>. <a
                href="#TableSystReview">Table 1</a> summarizes the
                studies providing information on PCOS prevalence in
                transmasculine people from the early 2000s to early
                2025. A few studies published before the Rotterdam
                diagnostic criteria (2003) were excluded due to
                methodological reasons (non-standardized and outdated
                diagnostic criteria, convenience samples, very small
                sample sizes, etc.), as their value was considered
                minimal.</p>
                <p><a id="TableSystReview"></a> <em>Table 1. Results of
                Systematic Literature Review of studies providing
                information on PCOS prevalence in transmasculine
                people</em></p>
                <div class="table-container-fullstretch">
                <table>
                <colgroup>
                <col style="width: 12%" />
                <col style="width: 12%" />
                <col style="width: 12%" />
                <col style="width: 12%" />
                <col style="width: 12%" />
                <col style="width: 12%" />
                <col style="width: 12%" />
                <col style="width: 12%" />
                </colgroup>
                <thead>
                <tr>
                <th>Study</th>
                <th>Country</th>
                <th>Sample size</th>
                <th>Study type</th>
                <th>Diagnostic criteria</th>
                <th>PCOS Prevalence</th>
                <th>Control group ?</th>
                <th>Distribution of Rotterdam phenotypes</th>
                </tr>
                </thead>
                <tbody>
                <tr>
                <td><span class="citation"
                data-cites="mueller_prevalence_2008">(<a
                href="#ref-mueller_prevalence_2008"
                role="doc-biblioref">Mueller et al.,
                2008</a>)</span></td>
                <td>Germany</td>
                <td>n=61</td>
                <td>Cross-sectional pre-HRT assessment</td>
                <td>Rotterdam ; NIH 1990</td>
                <td>14.8% ; 11.5%</td>
                <td>✅ ; No difference (94 cis women)</td>
                <td>❓ but similar to controls</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="vujovic_transsexualism_2009">(<a
                href="#ref-vujovic_transsexualism_2009"
                role="doc-biblioref">Vujovic et al.,
                2009</a>)</span></td>
                <td>Serbia</td>
                <td>n=76</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>Rotterdam</td>
                <td>14.4%</td>
                <td>❌</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="baba_distinctive_2011">(<a
                href="#ref-baba_distinctive_2011"
                role="doc-biblioref">Baba et al., 2011</a>)</span></td>
                <td>Japan</td>
                <td>n=238</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>Rotterdam ; NIH 1990 ; AES</td>
                <td>32% ; 17% ; 25.8%</td>
                <td>❌</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="auer_twenty_2013">(<a
                href="#ref-auer_twenty_2013" role="doc-biblioref">Auer
                et al., 2013</a>)</span></td>
                <td>Germany</td>
                <td>n=131</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>AES (similar)</td>
                <td>2.3%</td>
                <td>❌</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="becerra-fernandez_prevalencia_2014">(<a
                href="#ref-becerra-fernandez_prevalencia_2014"
                role="doc-biblioref">Becerra-Fernández et al.,
                2014</a>)</span></td>
                <td>Spain</td>
                <td>n=77</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>Rotterdam</td>
                <td>36.4%</td>
                <td>❌</td>
                <td>Oligo/anovulation: 64.3%; PCOM: 42.8%; Hirsutism:
                15.8%</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="kutbay_approach_2017">(<a
                href="#ref-kutbay_approach_2017"
                role="doc-biblioref">Kutbay et al.,
                2017</a>)</span></td>
                <td>Turkey</td>
                <td>n=48</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>❓</td>
                <td>16.3%</td>
                <td>❌</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="valentine_multicenter_2021">(<a
                href="#ref-valentine_multicenter_2021"
                role="doc-biblioref">Valentine et al.,
                2021</a>)</span></td>
                <td>United States</td>
                <td>n=4177</td>
                <td>Retrospective</td>
                <td>❓</td>
                <td>OR 1.9 [95% CI: 1.3, 2.8]</td>
                <td>✅ 4 matched without dysphoria diagnosis</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="yaish_functional_2021">(<a
                href="#ref-yaish_functional_2021"
                role="doc-biblioref">Yaish et al., 2021</a>)</span></td>
                <td>Israel</td>
                <td>n=56</td>
                <td>Prospective pre-HRT assessment</td>
                <td>Rotterdam</td>
                <td>48.2%</td>
                <td>❌</td>
                <td>PhA : 18% PhB : 70% PhC : 11% PhD : 0%</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="gezer_comparison_2022">(<a
                href="#ref-gezer_comparison_2022"
                role="doc-biblioref">Gezer et al., 2022</a>)</span></td>
                <td>Turkey</td>
                <td>n=49</td>
                <td>Cross-sectional pre-HRT assessment</td>
                <td>Rotterdam</td>
                <td>38.8%</td>
                <td>❌</td>
                <td>PhA : 26.3% PhB : 47.4% PhC : 15.8% PhD : 10.5%</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="vehmas_somatic_2022">(<a
                href="#ref-vehmas_somatic_2022"
                role="doc-biblioref">Vehmas et al.,
                2022</a>)</span></td>
                <td>Finland</td>
                <td>n=104</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>❓</td>
                <td>1.9%</td>
                <td>❌</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="erel_hyperandrogenismrelated_2023">(<a
                href="#ref-erel_hyperandrogenismrelated_2023"
                role="doc-biblioref">Erel et al., 2023</a>)</span></td>
                <td>Turkey</td>
                <td>n=70</td>
                <td>Cross-sectional pre-HRT assessment</td>
                <td>Rotterdam</td>
                <td>22.9%</td>
                <td>✅ ; 11.7% 34 cis women</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="oguz_prevalence_2023">(<a
                href="#ref-oguz_prevalence_2023"
                role="doc-biblioref">Oğuz et al., 2023</a>)</span></td>
                <td>Turkey</td>
                <td>n=112</td>
                <td>Cross-sectionnal pre-HRT assessment</td>
                <td>Rotterdam</td>
                <td>38.4%</td>
                <td>❌</td>
                <td>PhA : 20.9% PhB : 27.9% PhC : 46.5% PhD : 4.6%</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="rangi_prevalence_2024">(<a
                href="#ref-rangi_prevalence_2024"
                role="doc-biblioref">Rangi et al., 2024</a>)</span></td>
                <td>United States</td>
                <td>n=105</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>Non-standard criteria (oligo/anovulation +
                hyperandrogenism)</td>
                <td>23.8%</td>
                <td>❌</td>
                <td>❓</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="calvar_prevalence_2025">(<a
                href="#ref-calvar_prevalence_2025"
                role="doc-biblioref">Calvar et al.,
                2025</a>)</span></td>
                <td>Argentina</td>
                <td>n=346</td>
                <td>Retrospective pre-HRT assessment</td>
                <td>Rotterdam</td>
                <td>26.6%</td>
                <td>❌</td>
                <td>PhA : 33.7% PhB : 39.1% PhC : 20.7% PhD : 6.5%</td>
                </tr>
                <tr>
                <td><span class="citation"
                data-cites="tordoff_chronic_2025">(<a
                href="#ref-tordoff_chronic_2025"
                role="doc-biblioref">Tordoff et al.,
                2025</a>)</span></td>
                <td>United States</td>
                <td>n=2579</td>
                <td>Cross-sectional survey</td>
                <td>Self-reported questionnaire</td>
                <td>10.7%</td>
                <td>❌</td>
                <td>❓</td>
                </tr>
                </tbody>
                </table>
                </div>
                <p>These studies often, but not always, find a high
                prevalence of PCOS (typically based on the Rotterdam
                criteria) in transmasculine people, or at least higher
                than estimates in cisgender women. Numerous biases
                prevent concluding that PCOS prevalence is higher in
                transmasculine individuals, such as the <strong>absence
                of a control group</strong>, especially since PCOS
                prevalence, features, and attitudes towards care-seeking
                can vary significantly by geographical location,
                ethnicity, and other characteristics <span
                class="citation"
                data-cites="teede_recommendations_2023 sendur_influence_2021 vanhise_racial_2023">(<a
                href="#ref-sendur_influence_2021"
                role="doc-biblioref">Sendur &amp; Yildiz, 2021</a>; <a
                href="#ref-teede_recommendations_2023"
                role="doc-biblioref">Teede et al., 2023</a>; <a
                href="#ref-vanhise_racial_2023"
                role="doc-biblioref">VanHise et al., 2023</a>)</span>,
                or the <strong>retrospective nature of the
                studies</strong>: excluding Valentine et al. <span
                class="citation"
                data-cites="valentine_multicenter_2021">(<a
                href="#ref-valentine_multicenter_2021"
                role="doc-biblioref">2021</a>)</span> and Tordoff et al.
                <span class="citation"
                data-cites="tordoff_chronic_2025">(<a
                href="#ref-tordoff_chronic_2025"
                role="doc-biblioref">2025</a>)</span>, which were not
                designed with systematic PCOS screening in mind,
                two-thirds are retrospective studies, with the remaining
                one-third being cross-sectional.</p>
                <p>However, it is important to note some strengths:
                compared to older studies, most of the studies presented
                here use well-defined diagnostic criteria and decent
                sample sizes, even if they only examine individuals
                seeking hormone therapy.</p>
                <p>Two somewhat different studies stand out:
                Valentine et al. <span class="citation"
                data-cites="valentine_multicenter_2021">(<a
                href="#ref-valentine_multicenter_2021"
                role="doc-biblioref">2021</a>)</span>, a retrospective
                case-control study on a large pediatric database in the
                United States, and Tordoff et al. <span class="citation"
                data-cites="tordoff_chronic_2025">(<a
                href="#ref-tordoff_chronic_2025"
                role="doc-biblioref">2025</a>)</span>, a
                questionnaire-based analysis from the PRIDE cohort.
                Valentine et al. does not provide PCOS prevalence among
                young people with gender dysphoria but indicates it is
                1.9 times higher than matched controls. However, control
                matching did not account for many important covariates,
                and a strong bias of overdiagnosis in transmasculine
                youth is likely, rendering this figure ultimately
                uninformative. For example, cisgender young women will
                only be diagnosed with PCOS if they report symptoms,
                whereas many individuals with gender dysphoria seeking
                hormone therapy will undergo pre-HRT screening and thus
                have a higher chance of being diagnosed with PCOS. On
                the other hand, Tordoff et al. reports a PCOS prevalence
                of 10.7% among 2579 transmasculine individuals, similar
                to cisgender women, based on self-reported diagnoses,
                which includes diagnostic rates rather than just
                prevalence itself.</p>
                <p>In conclusion: - <strong>Outdated</strong>,
                methodologically weak studies in a <strong>stigmatizing
                etiological research context</strong> found PCOS
                prevalences in transmasculine individuals much higher
                than in cisgender women. - More recent and less
                methodologically flawed studies yield mixed results,
                suggesting <strong>PCOS prevalence in transmasculine
                people sometimes comparable to cisgender women and
                sometimes higher</strong>. - <strong>Methodological
                limitations prevent a definitive conclusion</strong>,
                beyond a simple “transmasculine individuals may have a
                higher PCOS prevalence than cisgender women,” despite a
                substantial number of studies—highlighting the
                <strong>issues with research priorities in transgender
                health</strong>.</p>
                <h3 data-number="2.3"
                id="what-these-results-reveal-about-research-priorities-in-transgender-health"><span
                class="header-section-number">2.3</span> What These
                Results Reveal About Research Priorities in Transgender
                Health</h3>
                <p>One of the main findings of the systematic review is
                the surprisingly high number of studies assessing PCOS
                prevalence in transmasculine individuals—especially when
                compared to the absence of studies examining the impact
                of HRT on those with concomitant PCOS; and their
                respective low quality. As usual, <strong>cisgender
                researchers study transgender people to understand what
                makes them transgender</strong> (with the very real
                possibility that these results may be used to restrict
                who is “allowed” to be transgender), <strong>but they do
                not seem concerned about data that could be useful to
                the marginalized populations they study</strong>.</p>
                <p>Almost all of these studies focus on mandatory
                assessments for individuals seeking HRT—primarily in
                dedicated transgender healthcare centers where
                participation in such studies is not truly optional.
                This raises ethical concerns, especially for studies
                that will not benefit other transgender people.</p>
                <p>Indeed, it is important to note that
                <strong>participating in these studies offers no
                benefits to the transgender individuals
                involved</strong>, neither personally nor from a broader
                perspective given the overall lack of utility of these
                studies. On the contrary, it imposes unnecessary and
                sometimes invasive examinations such as pelvic
                ultrasounds or body hair assessments. Of note, those
                examinations are part of a <strong>long-standing
                tradition of excluding intersex people</strong> from
                institutionalized transgender healthcare.</p>
                <p>Earlier, I mentioned that these studies were
                primarily conducted in the context of etiological
                research that does not benefit the individuals under
                study. However, while this context persists, more recent
                studies <strong>focus on cardiometabolic risk
                factors</strong>, highlighting that transmasculine
                individuals seeking HRT often have unfavorable and/or
                less favorable cardiometabolic risk factors compared to
                cisgender women in the general population—and this is
                even more pronounced for those with PCOS. While this
                information is not entirely irrelevant, it is not
                particularly useful either. Transgender people in
                general face numerous cardiometabolic risk factors,
                likely primarily due to their socio-economic
                precariousness and the consequences of minority stress
                <span class="citation"
                data-cites="flentje_minority_2025 streed_assessing_2021 diamond_systemic_2021">(<a
                href="#ref-diamond_systemic_2021"
                role="doc-biblioref">Diamond et al., 2021</a>; <a
                href="#ref-flentje_minority_2025"
                role="doc-biblioref">Flentje et al., 2025</a>; <a
                href="#ref-streed_assessing_2021"
                role="doc-biblioref">Streed et al., 2021</a>)</span>.
                <strong>Framing PCOS as the sole (or even main)
                determinant of these risk factors is politically
                counterproductive, essentializing the health
                consequences of experienced discrimination</strong>.
                Furthermore, these risk factors are easily measurable,
                and given the focus on hormone treatments, a genuine
                preventive approach to transgender health would benefit
                more from studies on the impact of PCOS on testosterone
                therapy than from studies on pre-testosterone health
                status.</p>
                <h2 data-number="3"
                id="does-testosterone-therapy-cause-pcos-in-transmasculine-individuals"><span
                class="header-section-number">3</span> Does Testosterone
                Therapy Cause PCOS in Transmasculine Individuals?</h2>
                <p>It is sometimes claimed that testosterone therapy in
                transmasculine individuals “causes” PCOS or a condition
                similar to PCOS—an <strong>intuitive idea given the
                common conception of PCOS as</strong>, roughly speaking,
                <strong>an excess of testosterone</strong>. However,
                <strong>this is not accurate</strong>: PCOS extends far
                beyond high testosterone levels, and its pathophysiology
                is complex. It is now well established that testosterone
                therapy and PCOS are two distinct situations.</p>
                <p>We can examine two main aspects: metabolic changes
                and reproductive system modifications.</p>
                <h3 data-number="3.1"
                id="metabolic-changes-evolution-towards-a-typical-male-profile-distinct-from-pcos"><span
                class="header-section-number">3.1</span> Metabolic
                Changes: Evolution Towards a Typical Male Profile,
                Distinct from PCOS</h3>
                <p>PCOS is characterized, among other things, by a
                rather specific metabolic profile marked notably by
                insulin resistance issues <span class="citation"
                data-cites="unfer_when_2024">(<a
                href="#ref-unfer_when_2024" role="doc-biblioref">Unfer
                et al., 2024</a>)</span>. The metabolic profile of cis
                women with PCOS differs from transmasculine individuals
                on testosterone therapy, whose metabolic profile
                generally resembles that of typical cisgender men.</p>
                <p>These patterns were examined in Cupisti et al. <span
                class="citation" data-cites="cupisti_impact_2010">(<a
                href="#ref-cupisti_impact_2010"
                role="doc-biblioref">2010</a>)</span>’s cohort study.
                This study investigates insulin resistance and lipid
                parameters in transmasculine individuals
                (pre-testosterone and at 1 year of testosterone
                treatment, n=29) compared to cisgender women with PCOS.
                The authors found that testosterone therapy did not
                influence insulin resistance and while lipid parameters
                changed with testosterone, they resulted in a different
                profile from cisgender women with PCOS.</p>
                <p>On the same topic, Chan et al. <span class="citation"
                data-cites="chan_exogenous_2018">(<a
                href="#ref-chan_exogenous_2018"
                role="doc-biblioref">2018</a>)</span>’s retrospective
                analysis examines the evolution of metabolic profiles
                (HbA1c and lipids) in transmasculine individuals (n=34)
                during their testosterone treatment over 6 years,
                compared to typical female (with or without PCOS) and
                male profiles. The authors found that the metabolic
                profile of individuals on testosterone evolved towards a
                typical male profile rather than a female PCOS
                profile.</p>
                <p>These studies are interesting in their direct
                comparisons between testosterone therapy and PCOS but
                remain limited, particularly in sample size. A recent
                meta-analysis by Tienforti et al. <span class="citation"
                data-cites="tienforti_metabolic_2024">(<a
                href="#ref-tienforti_metabolic_2024"
                role="doc-biblioref">2024</a>)</span> focusing on the
                metabolic aspects of transmasculine individuals on
                testosterone (BMI, waist-to-hip ratio, body composition,
                lipid and glycemic profiles) provides a robust global
                overview of the subject and <strong>clearly demonstrates
                metabolic changes aligning with typical male values
                rather than PCOS-associated ones</strong>.</p>
                <h3 data-number="3.2"
                id="reproductive-system-modifications-sometimes-polycystic-ovaries-but-distinct-changes-from-pcos"><span
                class="header-section-number">3.2</span> Reproductive
                System Modifications: Sometimes Polycystic Ovaries, but
                Distinct Changes from PCOS</h3>
                <p>PCOS is also characterized by a specific ovarian
                morphology (polycystic morphology), referred to as PCOM:
                polycystic ovarian morphology. <strong>This PCO
                morphology is not, despite its name, simply defined by
                the presence of multiple ovarian cysts</strong>.</p>
                <p>The “cysts” in PCOS are not true cysts; <strong>they
                are actually follicles</strong> (ovarian structures that
                secrete hormones and contain an oocyte) <strong>whose
                development was prematurely halted</strong> and instead
                of disappearing (through follicular atresia), they
                accumulate, forming a structure resembling numerous
                small cysts <span class="citation"
                data-cites="balen_ultrasound_2003 chang_disordered_2013 witchel_polycystic_2019">(<a
                href="#ref-balen_ultrasound_2003"
                role="doc-biblioref">Balen et al., 2003</a>; <a
                href="#ref-chang_disordered_2013"
                role="doc-biblioref">Chang &amp; Cook-Andersen,
                2013</a>; <a href="#ref-witchel_polycystic_2019"
                role="doc-biblioref">Witchel et al.,
                2019</a>)</span>.</p>
                <p>In the Rotterdam criteria <span class="citation"
                data-cites="therotterdameshre/asrm-sponsoredpcosconsensusworkshopgroup_revised_2004">(<a
                href="#ref-therotterdameshre/asrm-sponsoredpcosconsensusworkshopgroup_revised_2004"
                role="doc-biblioref">2004</a>)</span>, PCO morphology is
                defined by the presence of at least 12 follicles
                measuring 2-9 mm in diameter per ovary and/or
                significant ovarian volume (≥10 mL) on ultrasound.</p>
                <p>The appearance (echogenicity, volume, density) of the
                ovarian stroma (ovarian connective tissue) is mentioned
                as one of the characteristics of PCO morphology but is
                not required for diagnosis; ovarian volume being a good
                substitute <span class="citation"
                data-cites="balen_ultrasound_2003">(<a
                href="#ref-balen_ultrasound_2003"
                role="doc-biblioref">Balen et al., 2003</a>)</span>.</p>
                <p>Today, due to improved ultrasound techniques,
                counting follicles (or measuring AMH, see below) is
                preferred, defining <strong>PCO morphology starting from
                20 follicles per ovary</strong> <span class="citation"
                data-cites="teede_recommendations_2023">(<a
                href="#ref-teede_recommendations_2023"
                role="doc-biblioref">Teede et al., 2023</a>)</span>.
                These new criteria emphasize that <strong>PCO morphology
                is common and, on its own, does not indicate
                PCOS</strong>. This morphology is particularly frequent
                in younger individuals (60% of those aged 25-30 <span
                class="citation"
                data-cites="johnstone_polycystic_2010">(<a
                href="#ref-johnstone_polycystic_2010"
                role="doc-biblioref">Johnstone et al., 2010</a>)</span>
                and higher still in adolescents) and when using a lower
                threshold than 20 follicles. Sometimes multicystic
                ovaries are mentioned for a significant but smaller
                number of follicles, generally slightly larger than in
                polycystic ovaries, with a more typical stromal
                appearance <span class="citation"
                data-cites="balen_ultrasound_2003">(<a
                href="#ref-balen_ultrasound_2003"
                role="doc-biblioref">Balen et al., 2003</a>)</span>.</p>
                <p>As this morphology, which was more strongly
                associated with PCOS in the past, is partially linked to
                androgens (see inset below), both in PCOS and in many
                animal models, it was long believed that testosterone
                therapy inevitably induced PCO morphology in
                transmasculine individuals.</p>
                <div class="inset">
                <details>
                <summary>
                <strong>Inset: Formation of PCO Morphology and the
                Possible Role of Androgens</strong>
                </summary>
                <p>Follicles develop in cycles, continuously. Initially,
                multiple follicles start to grow, progressing from the
                primordial to primary, then secondary, and finally
                tertiary stages. At this point, the majority of the
                developing follicle group undergoes follicular atresia,
                and the remaining few continue as antral follicles.
                Gradually, all but one follicle undergo atresia; this
                dominant follicle rapidly develops into the
                pre-ovulatory follicle, releases its oocyte (ovulation),
                becomes a corpus luteum, and then dies <span
                class="citation" data-cites="cox_embryology_2025">(<a
                href="#ref-cox_embryology_2025" role="doc-biblioref">Cox
                &amp; Takov, 2025</a>)</span>.</p>
                This process (folliculogenesis) is regulated by complex
                hormonal mechanisms that can dysfunction. It is
                generally hypothesized that excess androgens can
                stimulate and block the development of follicles early
                in their life cycle (antral and pre-antral stages),
                leading to an accumulation of follicles that results in
                PCO morphology <span class="citation"
                data-cites="chang_disordered_2013">(<a
                href="#ref-chang_disordered_2013"
                role="doc-biblioref">Chang &amp; Cook-Andersen,
                2013</a>)</span>. However, many other factors are also
                at play. For instance, PCO morphology is also found in
                specific PCOS subtypes without androgen excess,
                suggesting a different mechanism <span class="citation"
                data-cites="unfer_when_2024">(<a
                href="#ref-unfer_when_2024" role="doc-biblioref">Unfer
                et al., 2024</a>)</span>.
                </details>
                </div>
                <p>This idea has only been confirmed by older studies,
                suffering from methodological flaws similar to those in
                prevalence studies: small samples, lack of control
                groups, variable and imprecise definitions, etc.</p>
                <p>A recent systematic review examining the ovaries
                (morphology, histopathology) of transmasculine
                individuals on testosterone therapy (11 studies, 410
                patients, 765 ovaries) found
                <strong>polycystic-appearing ovaries in ~35% of
                individuals</strong>—a proportion similar to the general
                population <span class="citation"
                data-cites="toland_uterine_2024">(<a
                href="#ref-toland_uterine_2024"
                role="doc-biblioref">Toland et al.,
                2024</a>)</span>.</p>
                <p>Additionally, results from studies with better
                methodology do not support the findings of these older
                studies. For instance, Ikeda et al. <span
                class="citation" data-cites="ikeda_excessive_2013">(<a
                href="#ref-ikeda_excessive_2013"
                role="doc-biblioref">2013</a>)</span> compared the
                ovaries of 11 transmasculine individuals on testosterone
                and control cisgender women, all without PCOS on
                histopathological grounds, and found
                <strong>histological changes similar to PCOS but no PCO
                morphology</strong> (according to Rotterdam criteria).
                The ovaries of individuals on testosterone had a thicker
                ovarian cortex and stromal hyperplasia, but the number
                of follicles (in early development and antral stage) was
                similar to controls. Subsequent studies draw similar
                conclusions, finding <strong>similar rates of PCO
                morphology in individuals on testosterone and
                controls</strong>. For a review, see the
                <em>Reproductive Health Considerations</em> section of
                Kumar et al. <span class="citation"
                data-cites="kumar_health_2022">(<a
                href="#ref-kumar_health_2022" role="doc-biblioref">2022,
                pp. 638–639</a>)</span>.</p>
                <p>In addition to typical ovarian morphology, PCOS is
                associated with <strong>elevated AMH (anti-Müllerian
                hormone) levels</strong>, which are sometimes used to
                aid in PCOS diagnosis and <strong>can be a diagnostic
                marker for PCO morphology</strong> (instead of ovarian
                volume/follicle count by ultrasound) <span
                class="citation"
                data-cites="dumont_role_2015 johnstone_polycystic_2010">(<a
                href="#ref-dumont_role_2015" role="doc-biblioref">Dumont
                et al., 2015</a>; <a
                href="#ref-johnstone_polycystic_2010"
                role="doc-biblioref">Johnstone et al., 2010</a>)</span>.
                This elevation may be linked to the frequently observed
                high androgen levels in PCOS. However, these findings
                once again do not extrapolate to transmasculine
                individuals on testosterone. <strong>There are few
                studies examining AMH changes with testosterone
                therapy</strong>, but results vary between a significant
                decrease in AMH and little to no impact—with <strong>no
                increase observed</strong> <span class="citation"
                data-cites="yaish_functional_2021">(<a
                href="#ref-yaish_functional_2021"
                role="doc-biblioref">Yaish et al., 2021</a>)</span>.</p>
                <p>The subtleties that may explain these observations
                are not well understood; there might be a threshold
                effect accounting for a different impact between
                moderately elevated testosterone levels (PCOS) and very
                high levels (testosterone therapy). There could also be
                specificities, distinct from simple androgenic activity,
                unique to PCOS. Thus, a prospective study assessing AMH
                levels in individuals starting testosterone found a
                slight decrease in AMH at 1 year of treatment. Upon
                subgroup analysis, the authors found that AMH levels
                decreased only in transmasculine individuals with PCOS
                (diagnosed before HRT) and did not change in others
                <span class="citation"
                data-cites="yaish_functional_2021">(<a
                href="#ref-yaish_functional_2021"
                role="doc-biblioref">Yaish et al., 2021</a>)</span>.</p>
                <p>In any case, these observations reinforce the idea
                that <strong>ovarian changes under testosterone therapy
                differ from those seen in PCOS</strong>.</p>
                <p>Another characteristic of PCOS is the frequent
                presence of a thick endometrium (&gt;7mm) due to chronic
                anovulation, which chronically exposes the endometrium
                to estrogen action without progesterone opposition <span
                class="citation" data-cites="unfer_when_2024">(<a
                href="#ref-unfer_when_2024" role="doc-biblioref">Unfer
                et al., 2024</a>)</span>. This anovulation is often
                associated with atypically high androgen levels. This
                increased endometrial thickness is a risk factor for
                endometrial hyperplasia and a possible explanation for
                the association between PCOS and an elevated risk of
                endometrial cancer.</p>
                <p>Once again, the situation in individuals on
                testosterone is very different. <strong>The endometrial
                thickness of individuals on testosterone is lower than
                that of controls</strong> <span class="citation"
                data-cites="asseler_endometrial_2022">(<a
                href="#ref-asseler_endometrial_2022"
                role="doc-biblioref">Asseler et al., 2022</a>)</span>,
                and endometrial hyperplasia is rare <span
                class="citation" data-cites="toland_uterine_2024">(<a
                href="#ref-toland_uterine_2024"
                role="doc-biblioref">Toland et al., 2024</a>)</span>.
                Furthermore, there does not appear to be an increased
                risk of endometrial cancer in individuals on
                testosterone <span class="citation"
                data-cites="vestering_incidence_2025">(<a
                href="#ref-vestering_incidence_2025"
                role="doc-biblioref">Vestering et al., 2025</a>)</span>,
                although more data are still needed.</p>
                <h3 data-number="3.3"
                id="if-pcos-and-testosterone-therapy-are-unrelated-why-these-comparisons"><span
                class="header-section-number">3.3</span> If PCOS and
                Testosterone Therapy Are Unrelated, Why These
                Comparisons?</h3>
                <p>The results presented above (metabolic changes) are
                not surprising: <strong>a shift towards a typical male
                profile under testosterone therapy (or female under
                estrogen) is nearly ubiquitous across a vast array of
                physiological parameters</strong>, ranging from common
                blood tests <span class="citation"
                data-cites="nolan_laboratory_2025">(<a
                href="#ref-nolan_laboratory_2025"
                role="doc-biblioref">Nolan &amp; Cheung,
                2025</a>)</span> to DNA methylation <span
                class="citation"
                data-cites="shepherd_genderaffirming_2022">(<a
                href="#ref-shepherd_genderaffirming_2022"
                role="doc-biblioref">Shepherd et al., 2022</a>)</span>
                and the fecal metagenome <span class="citation"
                data-cites="liwinski_genderaffirming_2024">(<a
                href="#ref-liwinski_genderaffirming_2024"
                role="doc-biblioref">Liwinski et al., 2024</a>)</span>
                (when differences exist between profiles, they are far
                from systematic).</p>
                <p><strong>Nevertheless, there is an insistence on
                comparing trans men to women and trans women to
                men</strong>; be it through constant comparisons between
                testosterone therapy and PCOS in scientific literature,
                especially when assessing HRT risks despite their lack
                of connection, or by calculating the breast cancer risk
                in trans women compared to cis men, rather than cis
                women, which yields seemingly alarmingly, yet not
                necessarily representative, elevated rates.</p>
                <p>This comparison seems to stem from the
                <strong>underlying assumption that gender identity,
                emerging from both intimate experience and social
                construction, is merely ornamental. In this covertly
                transphobic framework, trans people are understood to
                change their gender but not their sex, contrasting with
                sex as a biological and supposedly fixed category, which
                is considered the primary variable in medicine</strong>.
                Thus, trans men and transmasculine individuals on HRT
                are framed as women taking testosterone. Given that PCOS
                is often understood through the lens of androgens, it is
                assumed that these two situations share many
                similarities, although this is not the case. PCOS is
                characterized by much more than androgens; they play a
                role in its pathophysiology without being definitively
                identified as the cause. Testosterone levels in PCOS and
                during testosterone therapy are vastly different.
                Furthermore, the psychological context and socioeconomic
                implications bear little resemblance between
                transmasculine individuals and cis women with PCOS—a
                distinction that is rarely, if ever, mentioned or
                accounted for.</p>
                <p>The unsuitability of those PCOS/testosterone HRT
                comparaisons is even more striking considering others,
                better suited comparaisons could be drawn. For instance,
                compairing with hypogondal cis men who take
                testosterone, or with transmasculine people who do not
                take HRT. Those alternatives would eliminate variables
                related to PCOS itself and make feature like
                testosterone levels or psychosocial contexts more
                comparable. However, these comparisons are rarely made
                in the scientific litterature. I believe <strong>this
                stems from researchers too often perceiving trans people
                as belonging to their assigned sex first and
                foremost</strong>.</p>
                <p>This transphobic bias underlying these comparisons
                has tangible effects: beyond <strong>constantly
                reminding trans individuals of their past gender
                assignment</strong>, fostering a hostile environment,
                these comparisons lead to <strong>premature conclusions,
                sometimes alarmist</strong> and often lacking nuance.
                <strong>They contribute nothing to research and instead
                create blind spots detrimental to trans people’s
                health</strong>. For instance, if one assumes that
                testosterone is not suitable for a “female” body
                (transmasculine), one might attribute all cardiovascular
                issues in transmasculine individuals on HRT solely to
                testosterone, neglecting the impact of minority stress.
                Conversely, if estrogens are considered fundamentally
                incompatible with “male” bodies (transfeminine), one may
                wish to blame estrogen itself for health issues like
                osteoporosis in transfeminine individuals without
                considering they might be consequences of the
                underdosing they are frequently subjected to.</p>
                <h2 data-number="4"
                id="pcos-and-testosterone-therapy-a-rather-limited-impact"><span
                class="header-section-number">4</span> PCOS and
                Testosterone Therapy: A Rather Limited Impact</h2>
                <p>After extensively discussing transmasculine
                individuals without PCOS (who, as we’ve seen, will not
                develop it due to testosterone therapy), it’s time to
                address the topic of those with PCOS who wish to take
                testosterone.</p>
                <h3 data-number="4.1" id="general-considerations"><span
                class="header-section-number">4.1</span> General
                Considerations</h3>
                <p><strong>PCOS is by no means a contraindication for
                testosterone therapy.</strong></p>
                <p>If PCOS is suspected, it is advisable to establish
                the diagnosis before starting testosterone (which can
                complicate or prevent future diagnosis). However,
                <strong>diagnosing PCOS should not delay the initiation
                of hormone therapy</strong>.</p>
                <p>In line with 2023 international recommendations <span
                class="citation"
                data-cites="teede_recommendations_2023">(<a
                href="#ref-teede_recommendations_2023"
                role="doc-biblioref">Teede et al., 2023</a>)</span>,
                <strong>clinical assessment and blood tests are
                sufficient for diagnosis</strong>
                (<abbr title="Total estosterone">TT</abbr>,
                <abbr title="Estradiol">E2</abbr>,
                <abbr title="Luteinizing hormone">LH</abbr>,
                <abbr title="Follicle-stimulating Hormone">FSH</abbr>,
                <abbr title="Full blood count">FBC</abbr>,
                <abbr title="Fasting plasma glucose">FPG</abbr>, lipid
                panel, <abbr title="Liver function tests">LFT</abbr>),
                and serve as a pre-HRT health assessment and diagnostic
                tool for PCOS. AMH levels can be used in place of
                follicle counting to <strong>avoid pelvic
                ultrasound</strong> (usually transvaginal), as
                alternatives to gynecological examinations should be
                prioritized when possible for transmasculine
                individuals, who often find them distressing.</p>
                <p><img
                src="recommended-diagnostic-pathway-pcos-2023.png"
                alt="Figure of diagnostic pathway from 2023 recommendations found in Teede et al. 2023" />
                <em>Diagnostic pathway taken from Teede et al. <span
                class="citation"
                data-cites="teede_recommendations_2023">(<a
                href="#ref-teede_recommendations_2023"
                role="doc-biblioref">2023, p. G60</a>)</span>. Consult
                the original for further details.</em></p>
                <p>Additionally, <strong>PCOS does not require dosage
                adjustments</strong> from standard testosterone therapy
                protocols. Elevated androgen levels pre-HRT are not
                always present, and when they are, they remain
                negligible compared to typical target levels under
                testosterone therapy. As a result, one can simply start
                with a standard dosage and adjust it based on blood test
                results and subjective experience.</p>
                <h3 data-number="4.2"
                id="impact-on-health-a-critical-lack-of-information-but-reassuring-data"><span
                class="header-section-number">4.2</span> Impact on
                Health: A Critical Lack of Information but Reassuring
                Data</h3>
                <p>PCOS is associated with an increased risk of certain
                health issues, and testosterone therapy can influence
                these risks.</p>
                <h4 data-number="4.2.1"
                id="insulin-resistance-and-cardiovascular-diseases"><span
                class="header-section-number">4.2.1</span> Insulin
                Resistance and Cardiovascular Diseases</h4>
                <p>PCOS is linked to various cardiovascular risk factors
                (insulin resistance, diabetes, dyslipidemia) and a
                higher risk of cardiovascular diseases. <strong>It is
                recommended to conduct a glycemic and lipid profile at
                the time of diagnosis and to monitor glycemic status
                (ideally with
                <abbr title="Oral Glucose Tolerance Test">OGTT</abbr>,
                otherwise <abbr title="Hemoglobin A1C">HbA1c</abbr> +
                <abbr title="Fasting Plasma Glucose">FPG</abbr>) every
                1-3 years</strong>.</p>
                <p>Testosterone therapy in transmasculine individuals is
                frequently associated with some of these cardiovascular
                risk factors, and sometimes, but not always, with an
                increased risk or mortality from cardiovascular
                diseases. It should be noted that the causality of this
                relationship is far from established. Factors such as
                minority stress may also contribute, and studies on
                trans individuals show a higher risk compared to cis
                individuals, but not compared to trans individuals not
                on HRT <span class="citation"
                data-cites="karalexi_cardiovascular_2022 glintborg_cardiovascular_2022">(<a
                href="#ref-glintborg_cardiovascular_2022"
                role="doc-biblioref">Glintborg et al., 2022</a>; <a
                href="#ref-karalexi_cardiovascular_2022"
                role="doc-biblioref">Karalexi et al., 2022</a>)</span>,
                <strong>suggesting a role for trans-specific factors
                (socioeconomic precariousness, minority stress, etc.)
                rather than HRT</strong>.</p>
                <p>From the perspective of lipids, testosterone appears
                to have a slightly unfavorable effect. Regarding insulin
                resistance, testosterone seems to have a mildly
                beneficial effect <span class="citation"
                data-cites="tienforti_metabolic_2024">(<a
                href="#ref-tienforti_metabolic_2024"
                role="doc-biblioref">Tienforti et al.,
                2024</a>)</span>.</p>
                <p>The interaction between the effects of PCOS and
                testosterone therapy, which operate through different
                mechanisms, is barely understood. However,
                encouragingly, a recent retrospective analysis of
                transmasculine individuals with or without PCOS starting
                testosterone found <strong>no greater cardiovascular
                risk factor changes in those with PCOS</strong> <span
                class="citation" data-cites="mcneil_sun510_2024">(<a
                href="#ref-mcneil_sun510_2024"
                role="doc-biblioref">McNeil et al.,
                2024</a>)</span>.</p>
                <p><strong>It is plausible that testosterone has a
                positive, or at least neutral, effect on insulin
                resistance in PCOS</strong>, but data are severely
                lacking. Therefore, it seems reasonable to simply follow
                the monitoring recommendations for cis women with PCOS
                (glycemic status surveillance), adjusted according to
                clinical presentation, in line with Fenway Health <span
                class="citation" data-cites="thompson_medical_2021">(<a
                href="#ref-thompson_medical_2021"
                role="doc-biblioref">Thompson et al., 2021</a>)</span>
                and UCSF guidelines <span class="citation"
                data-cites="deutsch_guidelines_2016">(<a
                href="#ref-deutsch_guidelines_2016"
                role="doc-biblioref">Deutsch, 2016</a>)</span>.</p>
                <h4 data-number="4.2.2"
                id="endometrial-hyperplasia-and-cancer"><span
                class="header-section-number">4.2.2</span> Endometrial
                Hyperplasia and Cancer</h4>
                <p>As mentioned earlier, PCOS is often associated with a
                thick endometrium, a risk factor for endometrial
                hyperplasia and cancer. <strong>Since the absolute risk
                of endometrial cancer remains low, systematic screening
                is not recommended</strong> for cis women with PCOS.
                However, information and prevention measures are
                advised. In cis women with PCOS, ovulation problems are
                considered responsible for endometrial thickening:
                chronic anovulation alters the menstrual cycle, leading
                to prolonged exposure of the endometrium to estrogen
                action without progesterone opposition. Progesterone
                typically prevents endometrial proliferation. Chronic
                amenorrhea (absence of periods) is a marker of this
                process.</p>
                <p>Similarly, it was often assumed that transmasculine
                individuals taking testosterone were at higher risk of
                endometrial cancer. It was hypothesized that the
                estradiol into which some of the administered
                testosterone metabolizes could cause endometrial
                proliferation, or that the androgenic action of
                testosterone itself might be directly responsible.
                However, more recent data are reassuring: androgen
                activity on the endometrium is complex but tends to be
                antiproliferative <span class="citation"
                data-cites="gjorgoska_integration_2022">(<a
                href="#ref-gjorgoska_integration_2022"
                role="doc-biblioref">Gjorgoska &amp; Rizner,
                2022</a>)</span>, and in transmasculine individuals on
                testosterone, the endometrium thins <span
                class="citation"
                data-cites="asseler_endometrial_2022">(<a
                href="#ref-asseler_endometrial_2022"
                role="doc-biblioref">Asseler et al., 2022</a>)</span>
                and is rarely hyperplastic <span class="citation"
                data-cites="toland_uterine_2024">(<a
                href="#ref-toland_uterine_2024"
                role="doc-biblioref">Toland et al., 2024</a>)</span>.
                Additionally, there does not appear to be an increased
                risk of endometrial cancer with testosterone therapy,
                whether in postmenopausal cis women or transmasculine
                individuals <span class="citation"
                data-cites="vestering_incidence_2025">(<a
                href="#ref-vestering_incidence_2025"
                role="doc-biblioref">Vestering et al., 2025</a>)</span>,
                although data remain limited. Therefore, <strong>it is
                conceivable that testosterone has a positive or at least
                neutral effect on the risk of endometrial cancer
                associated with PCOS</strong>. Thus, no specific
                monitoring seems necessary.</p>
                <h4 data-number="4.2.3" id="mental-health"><span
                class="header-section-number">4.2.3</span> Mental
                Health</h4>
                <p>In cis women, it is now recognized that PCOS is
                associated with poorer mental health: depression,
                anxiety, body image issues, eating disorders, and more
                <span class="citation"
                data-cites="teede_recommendations_2023">(<a
                href="#ref-teede_recommendations_2023"
                role="doc-biblioref">Teede et al., 2023</a>)</span>.
                This phenomenon cannot be disconnected from the gendered
                pressures and fatphobia cis women with PCOS commonly
                face.</p>
                <p>Given its intimate link to gender experience, it is
                unsurprising that transmasculine individuals’ lived
                experiences (and those of trans and queer people in
                general) may differ. For example, certain aspects like
                increased androgen presence or amenorrhea are often
                welcomed by transmasculine individuals, although
                individual experiences vary <span class="citation"
                data-cites="wugalter_doubleedged_2024">(<a
                href="#ref-wugalter_doubleedged_2024"
                role="doc-biblioref">Wugalter et al., 2024</a>)</span>.
                A study comparing transmasculine individuals with and
                without PCOS before HRT observed less gender dysphoria,
                better body image, and higher quality of life in those
                with PCOS <span class="citation"
                data-cites="gezer_comparison_2022">(<a
                href="#ref-gezer_comparison_2022"
                role="doc-biblioref">Gezer et al., 2022</a>)</span>.
                While data are severely lacking, <strong>it seems
                plausible that PCOS has positive effects on the mental
                health of transmasculine individuals</strong>
                (especially pre-/non-HRT), contrasting with cis women.
                However, PCOS likely remains associated with negative
                effects, particularly due to additional discrimination
                and barriers encountered.</p>
                <p>In any case, it is established that trans people’s
                mental health tends to be poorer than cis individuals’,
                especially due to minority stress and discrimination.
                These factors should be considered in trans individuals
                with PCOS, and efforts should be made to <strong>avoid
                exacerbating them, particularly through fatphobic
                behaviors</strong>.</p>
                <h3 data-number="4.3" id="fertility"><span
                class="header-section-number">4.3</span> Fertility</h3>
                <p>PCOS can impact fertility, primarily by causing
                ovulation problems but also by being associated with
                more complications during pregnancy (miscarriage,
                gestational diabetes, pre-eclampsia, etc.). The effects
                of testosterone on transmasculine individuals’ fertility
                are varied and still not well understood, but current
                data are reassuring. For a comprehensive review, see De
                Roo et al. <span class="citation"
                data-cites="deroo_fertility_2025">(<a
                href="#ref-deroo_fertility_2025"
                role="doc-biblioref">2025</a>)</span>.</p>
                <p>Data on the fertility of transmasculine individuals
                with PCOS on testosterone are even more limited. Studies
                often do not include information on whether participants
                have PCOS. One study mentioned earlier examining ovarian
                reserve markers in transmasculine individuals on
                testosterone, with or without PCOS, found a slight
                decrease in AMH levels with testosterone only in those
                with PCOS <span class="citation"
                data-cites="yaish_functional_2021">(<a
                href="#ref-yaish_functional_2021"
                role="doc-biblioref">Yaish et al., 2021</a>)</span>. A
                similar (but non-significant) trend was identified for
                follicle count. Both markers remained within normal
                ranges even in individuals with PCOS. The authors
                hypothesize that the greater decline in ovarian reserve
                in PCOS may be due to pre-testosterone differences or
                that testosterone has a different impact on those with a
                deregulated hypothalamic-pituitary-gonadal axis. They
                note that the duration of testosterone therapy does not
                seem to affect ovarian reserve, except possibly slightly
                in individuals with PCOS.</p>
                <p>Beyond these reassuring but limited data, <strong>the
                mechanisms of action on fertility differ between PCOS
                and testosterone in the context of HRT. There do not
                appear to be particular concerns regarding the
                fertility</strong> of individuals with PCOS who take
                testosterone (beyond the standard impact of PCOS and
                testosterone separately).</p>
                <p>If the use of one’s own gametes is desired,
                especially long-term, fertility preservation (egg
                freezing) should be considered before or within a few
                years of starting testosterone. Parental planning will
                typically need to be accompanied by discontinuing
                testosterone—although this recommendation is being
                challenged <span class="citation"
                data-cites="pfeffer_medical_2023">(<a
                href="#ref-pfeffer_medical_2023"
                role="doc-biblioref">Pfeffer et al., 2023</a>)</span>,
                and by receiving similar management to cis women with
                PCOS (treating anovulation and preventing
                complications).</p>
                <h3 data-number="4.4"
                id="in-practice-i-have-pcos-and-want-to-take-testosterone-what-should-i-do"><span
                class="header-section-number">4.4</span> In Practice: I
                Have PCOS and Want to Take Testosterone, What Should I
                Do?</h3>
                <p>Not much specific action is required, but here are
                some helpful points to know:</p>
                <ul>
                <li>If a formal diagnosis has’nt been made but you’d
                like it to be, it’s best to do so before starting
                testosterone. <strong>A vaginal ultrasound is not
                mandatory for diagnosis</strong> and nowadays can
                usually be replaced by a blood test.</li>
                <li>PCOS is not a contraindication for testosterone
                therapy and <strong>does not require any particular
                dosage adjustments</strong>. If you’re fat, you
                shouldn’t be required to lose weight before starting
                testosterone.</li>
                <li>If your doctor doesn’t offer it, ask for monitoring
                of your glycemic status; a blood test every 1-3 years is
                sufficient to detect and treat potential complications
                like diabetes early on.</li>
                <li>If your periods don’t return within a few months
                after stopping testosterone or if you experience
                prolonged vaginal bleeding while on testosterone
                (excluding dose changes and if it’s unusual for you),
                consult a doctor.</li>
                <li>If you have PCOS symptoms, including issues with
                insulin resistance, and are told that the treatment is
                to lose weight: this is <strong>fatphobia</strong> and
                not medically justified. Depending on your case, dietary
                modifications, physical exercise, and medication should
                be offered to you, taking into account your abilities
                and personal circumstances, <strong>with weight loss not
                being the primary goal</strong>; it’s generally not a
                very relevant variable.</li>
                </ul>
                <h1 class="unnumbered"
                id="bibliography">Bibliography</h1>
                <div id="refs"
                class="references csl-bib-body hanging-indent"
                data-entry-spacing="0" data-line-spacing="2"
                role="list">
                <div id="ref-asseler_endometrial_2022" class="csl-entry"
                role="listitem">
                Asseler, J. D., Caanen, M. R., Verhoeven, M. O., Huirne,
                J. A. F., Goddijn, M., Van Dulmen-den Broeder, E.,
                Overbeek, A., Lambalk, C. B., &amp; Van Mello, N. M.
                (2022). Endometrial thickness assessed by transvaginal
                ultrasound in transmasculine people taking testosterone
                compared with cisgender women. <em>Reproductive
                BioMedicine Online</em>, <em>45</em>(5), 1033–1038. <a
                href="https://doi.org/10.1016/j.rbmo.2022.06.012">https://doi.org/10.1016/j.rbmo.2022.06.012</a>
                </div>
                <div id="ref-auer_twenty_2013" class="csl-entry"
                role="listitem">
                Auer, M. K., Fuss, J., Stalla, G. K., &amp;
                Athanasoulia, A. P. (2013). Twenty years of
                endocrinologic treatment in transsexualism: Analyzing
                the role of chromosomal analysis and hormonal profiling
                in the diagnostic work-up. <em>Fertility and
                Sterility</em>, <em>100</em>(4), 1103–1110. <a
                href="https://doi.org/10.1016/j.fertnstert.2013.05.047">https://doi.org/10.1016/j.fertnstert.2013.05.047</a>
                </div>
                <div id="ref-baba_distinctive_2011" class="csl-entry"
                role="listitem">
                Baba, T., Endo, T., Ikeda, K., Shimizu, A., Honnma, H.,
                Ikeda, H., Masumori, N., Ohmura, T., Kiya, T., Fujimoto,
                T., Koizumi, M., &amp; Saito, T. (2011). Distinctive
                <span>Features</span> of <span
                class="nocase">Female-to-Male Transsexualism</span> and
                <span>Prevalence</span> of <span>Gender Identity
                Disorder</span> in <span>Japan</span>. <em>The Journal
                of Sexual Medicine</em>, <em>8</em>(6), 1686–1693. <a
                href="https://doi.org/10.1111/j.1743-6109.2011.02252.x">https://doi.org/10.1111/j.1743-6109.2011.02252.x</a>
                </div>
                <div id="ref-balen_ultrasound_2003" class="csl-entry"
                role="listitem">
                Balen, A. H., Laven, J. S. E., Tan, S.-L., &amp;
                Dewailly, D. (2003). Ultrasound assessment of the
                polycystic ovary: International consensus definitions.
                <em>Human Reproduction Update</em>, <em>9</em>(6),
                505–514. <a
                href="https://doi.org/10.1093/humupd/dmg044">https://doi.org/10.1093/humupd/dmg044</a>
                </div>
                <div id="ref-becerra-fernandez_prevalencia_2014"
                class="csl-entry" role="listitem">
                Becerra-Fernández, A., Pérez-López, G., Román, M. M.,
                Martín-Lazaro, J. F., Lucio Pérez, M. J., Asenjo Araque,
                N., Rodríguez-Molina, J. M., Berrocal Sertucha, M. C.,
                &amp; Aguilar Vilas, M. V. (2014). Prevalencia de
                hiperandrogenismo y síndrome de ovario poliquístico en
                transexuales de mujer a hombre. <em>Endocrinología y
                Nutrición</em>, <em>61</em>(7), 351–358. <a
                href="https://doi.org/10.1016/j.endonu.2014.01.010">https://doi.org/10.1016/j.endonu.2014.01.010</a>
                </div>
                <div id="ref-biyokea_prevalence_2025" class="csl-entry"
                role="listitem">
                biyokea. (2025). Prévalence du <span>SOPK</span> chez
                les personnes transmasculines : Une revue systématique
                de la littérature. <em>(Unpublished Data)</em>.
                </div>
                <div id="ref-calvar_prevalence_2025" class="csl-entry"
                role="listitem">
                Calvar, C. E., Di Noto, M., Lema Villacis, M., Blanco
                Hirota, N., &amp; Anticona Sayán, M. I. (2025).
                [Prevalence, phenotype distribution and cardiometabolic
                risk of polycystic ovarian syndrome in transgender
                population]. <em>Medicina</em>, <em>85</em>(1), 31–38.
                <a
                href="https://www.ncbi.nlm.nih.gov/pubmed/39900046">https://www.ncbi.nlm.nih.gov/pubmed/39900046</a>
                </div>
                <div id="ref-chan_exogenous_2018" class="csl-entry"
                role="listitem">
                Chan, K. J., Liang, J. J., Jolly, D., Weinand, J. D.,
                &amp; Safer, J. D. (2018). Exogenous <span>Testosterone
                Does Not Induce</span> or <span>Exacerbate</span> the
                <span>Metabolic Features Associated</span> with
                <span>Pcos Among Transgender Men</span>. <em>Endocrine
                Practice</em>, <em>24</em>(6), 565–572. <a
                href="https://doi.org/10.4158/EP-2017-0247">https://doi.org/10.4158/EP-2017-0247</a>
                </div>
                <div id="ref-chang_disordered_2013" class="csl-entry"
                role="listitem">
                Chang, R. J., &amp; Cook-Andersen, H. (2013). Disordered
                follicle development. <em>Molecular and Cellular
                Endocrinology</em>, <em>373</em>(1), 51–60. <a
                href="https://doi.org/10.1016/j.mce.2012.07.011">https://doi.org/10.1016/j.mce.2012.07.011</a>
                </div>
                <div id="ref-chiaffarino_prevalence_2022"
                class="csl-entry" role="listitem">
                Chiaffarino, F., Cipriani, S., Dalmartello, M., Ricci,
                E., Esposito, G., Fedele, F., La Vecchia, C., Negri, E.,
                &amp; Parazzini, F. (2022). Prevalence of polycystic
                ovary syndrome in <span>European</span> countries and
                <span>USA</span>: <span>A</span> systematic review and
                meta-analysis. <em>European Journal of Obstetrics &amp;
                Gynecology and Reproductive Biology</em>, <em>279</em>,
                159–170. <a
                href="https://doi.org/10.1016/j.ejogrb.2022.10.020">https://doi.org/10.1016/j.ejogrb.2022.10.020</a>
                </div>
                <div id="ref-cox_embryology_2025" class="csl-entry"
                role="listitem">
                Cox, E., &amp; Takov, V. (2025). Embryology,
                <span>Ovarian Follicle Development</span>. In
                <em><span>StatPearls</span></em>. StatPearls Publishing.
                <a
                href="http://www.ncbi.nlm.nih.gov/books/NBK532300/">http://www.ncbi.nlm.nih.gov/books/NBK532300/</a>
                </div>
                <div id="ref-cupisti_impact_2010" class="csl-entry"
                role="listitem">
                Cupisti, S., Giltay, E. J., Gooren, L. J., Kronawitter,
                D., Oppelt, P. G., Beckmann, M. W., Dittrich, R., &amp;
                Mueller, A. (2010). The impact of testosterone
                administration to female-to-male transsexuals on insulin
                resistance and lipid parameters compared with women with
                polycystic ovary syndrome. <em>Fertility and
                Sterility</em>, <em>94</em>(7), 2647–2653. <a
                href="https://doi.org/10.1016/j.fertnstert.2010.03.048">https://doi.org/10.1016/j.fertnstert.2010.03.048</a>
                </div>
                <div id="ref-deroo_fertility_2025" class="csl-entry"
                role="listitem">
                De Roo, C., Schneider, F., Stolk, T. H. R., Van Vugt, W.
                L. J., Stoop, D., &amp; Van Mello, N. M. (2025).
                Fertility in transgender and gender diverse people:
                Systematic review of the effects of gender-affirming
                hormones on reproductive organs and fertility. <em>Human
                Reproduction Update</em>, <em>31</em>(3), 183–217. <a
                href="https://doi.org/10.1093/humupd/dmae036">https://doi.org/10.1093/humupd/dmae036</a>
                </div>
                <div id="ref-deutsch_guidelines_2016" class="csl-entry"
                role="listitem">
                Deutsch, M. B. (2016, June 17). <em>Guidelines for the
                <span>Primary</span> and <span>Gender-Affirming
                Care</span> of <span>Transgender</span> and <span>Gender
                Nonbinary People</span> <span>Gender Affirming Health
                Program</span></em>. <a
                href="https://transcare.ucsf.edu/guidelines">https://transcare.ucsf.edu/guidelines</a>
                </div>
                <div id="ref-diguardo_male_2020" class="csl-entry"
                role="listitem">
                Di Guardo, F., Ciotta, L., Monteleone, M., &amp;
                Palumbo, M. (2020). Male <span>Equivalent Polycystic
                Ovarian Syndrome</span>: <span>Hormonal</span>,
                <span>Metabolic</span> and <span>Clinical
                Aspects</span>. <em>International Journal of Fertility
                and Sterility</em>, <em>14</em>(2). <a
                href="https://doi.org/10.22074/ijfs.2020.6092">https://doi.org/10.22074/ijfs.2020.6092</a>
                </div>
                <div id="ref-diamond_systemic_2021" class="csl-entry"
                role="listitem">
                Diamond, L. M., Dehlin, A. J., &amp; Alley, J. (2021).
                Systemic inflammation as a driver of health disparities
                among sexually-diverse and gender-diverse individuals.
                <em>Psychoneuroendocrinology</em>, <em>129</em>, 105215.
                <a
                href="https://doi.org/10.1016/j.psyneuen.2021.105215">https://doi.org/10.1016/j.psyneuen.2021.105215</a>
                </div>
                <div id="ref-dumont_role_2015" class="csl-entry"
                role="listitem">
                Dumont, A., Robin, G., Catteau-Jonard, S., &amp;
                Dewailly, D. (2015). Role of <span>Anti-Müllerian
                Hormone</span> in pathophysiology, diagnosis and
                treatment of <span>Polycystic Ovary Syndrome</span>: A
                review. <em>Reproductive Biology and Endocrinology</em>,
                <em>13</em>(1), 137. <a
                href="https://doi.org/10.1186/s12958-015-0134-9">https://doi.org/10.1186/s12958-015-0134-9</a>
                </div>
                <div id="ref-erel_hyperandrogenismrelated_2023"
                class="csl-entry" role="listitem">
                Erel, P., Elbasan, O., Yorguner, N., İmre, E., &amp;
                Üstay, Ö. (2023). Hyperandrogenism-related metabolic
                changes in drug-naïve transmen compared to cisgender
                women: A case-controlled study. <em>Endokrynologia
                Polska</em>, VM/OJS/J/95382. <a
                href="https://doi.org/10.5603/EP.a2023.0052">https://doi.org/10.5603/EP.a2023.0052</a>
                </div>
                <div id="ref-flentje_minority_2025" class="csl-entry"
                role="listitem">
                Flentje, A., Sunder, G., &amp; Tebbe, E. (2025).
                Minority stress in relation to biological outcomes among
                sexual and gender minority people: A systematic review
                and update. <em>Journal of Behavioral Medicine</em>,
                <em>48</em>(1), 22–42. <a
                href="https://doi.org/10.1007/s10865-024-00539-6">https://doi.org/10.1007/s10865-024-00539-6</a>
                </div>
                <div id="ref-gezer_comparison_2022" class="csl-entry"
                role="listitem">
                Gezer, E., Piro, B., Cantürk, Z., Çetinarslan, B.,
                Sözen, M., Selek, A., Polat Işik, A., &amp; Seal, L. J.
                (2022). The <span>Comparison</span> of <span>Gender
                Dysphoria</span>, <span>Body Image Satisfaction</span>
                and <span>Quality</span> of <span>Life Between
                Treatment-Naive Transgender Males With</span> and
                <span>Without Polycystic Ovary Syndrome</span>.
                <em>Transgender Health</em>, <em>7</em>(6), 514–520. <a
                href="https://doi.org/10.1089/trgh.2021.0061">https://doi.org/10.1089/trgh.2021.0061</a>
                </div>
                <div id="ref-gjorgoska_integration_2022"
                class="csl-entry" role="listitem">
                Gjorgoska, M., &amp; Rizner, T. L. (2022). Integration
                of androgen hormones in endometrial cancer biology.
                <em>Trends in Endocrinology &amp; Metabolism</em>,
                <em>33</em>(9), 639–651. <a
                href="https://doi.org/10.1016/j.tem.2022.06.001">https://doi.org/10.1016/j.tem.2022.06.001</a>
                </div>
                <div id="ref-glintborg_cardiovascular_2022"
                class="csl-entry" role="listitem">
                Glintborg, D., Rubin, K. H., Petersen, T. G., Lidegaard,
                Ø., T’Sjoen, G., Hilden, M., &amp; Andersen, M. S.
                (2022). Cardiovascular risk in <span>Danish</span>
                transgender persons: A matched historical cohort study.
                <em>European Journal of Endocrinology</em>,
                <em>187</em>(3), 463–477. <a
                href="https://doi.org/10.1530/EJE-22-0306">https://doi.org/10.1530/EJE-22-0306</a>
                </div>
                <div id="ref-ikeda_excessive_2013" class="csl-entry"
                role="listitem">
                Ikeda, K., Baba, T., Noguchi, H., Nagasawa, K., Endo,
                T., Kiya, T., &amp; Saito, T. (2013). Excessive androgen
                exposure in female-to-male transsexual persons of
                reproductive age induces hyperplasia of the ovarian
                cortex and stroma but not polycystic ovary morphology.
                <em>Human Reproduction</em>, <em>28</em>(2), 453–461. <a
                href="https://doi.org/10.1093/humrep/des385">https://doi.org/10.1093/humrep/des385</a>
                </div>
                <div id="ref-johnstone_polycystic_2010"
                class="csl-entry" role="listitem">
                Johnstone, E. B., Rosen, M. P., Neril, R., Trevithick,
                D., Sternfeld, B., Murphy, R., Addauan-Andersen, C.,
                McConnell, D., Pera, R. R., &amp; Cedars, M. I. (2010).
                The <span>Polycystic Ovary Post-Rotterdam</span>:
                <span>A Common</span>, <span>Age-Dependent
                Finding</span> in <span>Ovulatory Women</span> without
                <span>Metabolic Significance</span>. <em>The Journal of
                Clinical Endocrinology &amp; Metabolism</em>,
                <em>95</em>(11), 4965–4972. <a
                href="https://doi.org/10.1210/jc.2010-0202">https://doi.org/10.1210/jc.2010-0202</a>
                </div>
                <div id="ref-karalexi_cardiovascular_2022"
                class="csl-entry" role="listitem">
                Karalexi, M. A., Frisell, T., Cnattingius, S., Holmberg,
                D., Holmberg, M., Kollia, N., Skalkidou, A., &amp;
                Papadopoulos, F. C. (2022). Cardiovascular outcomes in
                transgender individuals in <span>Sweden</span> after
                initiation of gender-affirming hormone therapy.
                <em>European Journal of Preventive Cardiology</em>,
                <em>29</em>(15), 2017–2026. <a
                href="https://doi.org/10.1093/eurjpc/zwac133">https://doi.org/10.1093/eurjpc/zwac133</a>
                </div>
                <div id="ref-kumar_health_2022" class="csl-entry"
                role="listitem">
                Kumar, S., Mukherjee, S., O’Dwyer, C., Wassersug, R.,
                Bertin, E., Mehra, N., Dahl, M., Genoway, K., &amp;
                Kavanagh, A. G. (2022). Health <span>Outcomes Associated
                With Having</span> an <span>Oophorectomy Versus
                Retaining One</span>’s <span>Ovaries</span> for
                <span>Transmasculine</span> and <span>Gender Diverse
                Individuals Treated With Testosterone Therapy</span>:
                <span>A Systematic Review</span>. <em>Sexual Medicine
                Reviews</em>, <em>10</em>(4), 636–647. <a
                href="https://doi.org/10.1016/j.sxmr.2022.03.003">https://doi.org/10.1016/j.sxmr.2022.03.003</a>
                </div>
                <div id="ref-kutbay_approach_2017" class="csl-entry"
                role="listitem">
                Kutbay, N. O., Yurekli, B. S., Baykan, E. K., Ozbaran,
                N. B., Elbi, H., &amp; Saygili, F. (2017). Approach to
                transgender individuals. <em>The Egyptian Journal of
                Internal Medicine</em>, <em>29</em>(1), 1–4. <a
                href="https://doi.org/10.4103/1110-7782.207782">https://doi.org/10.4103/1110-7782.207782</a>
                </div>
                <div id="ref-lafci_pcos_2024" class="csl-entry"
                role="listitem">
                Lafci, N. G., Yilmaz, B., &amp; Yildiz, B. O. (2024).
                <span>PCOS</span> - the many faces of a disorder in
                women and men. <em>Journal of Endocrinological
                Investigation</em>. <a
                href="https://doi.org/10.1007/s40618-024-02512-1">https://doi.org/10.1007/s40618-024-02512-1</a>
                </div>
                <div id="ref-levin_biological_2023" class="csl-entry"
                role="listitem">
                Levin, R. N., Erickson-Schroth ,Laura, Mak ,Kristie,
                &amp; Edmiston, E. K. and. (2023). Biological studies of
                transgender identity: <span>A</span> critical review.
                <em>Journal of Gay &amp; Lesbian Mental Health</em>,
                <em>27</em>(3), 254–283. <a
                href="https://doi.org/10.1080/19359705.2022.2127042">https://doi.org/10.1080/19359705.2022.2127042</a>
                </div>
                <div id="ref-liwinski_genderaffirming_2024"
                class="csl-entry" role="listitem">
                Liwinski, T., Auer, M. K., Schröder, J., Pieknik, I.,
                Casar, C., Schwinge, D., Henze, L., Stalla, G. K., Lang,
                U. E., Von Klitzing, A., Briken, P., Hildebrandt, T.,
                Desbuleux, J. C., Biedermann, S. V., Holterhus, P.-M.,
                Bang, C., Schramm, C., &amp; Fuss, J. (2024).
                Gender-affirming hormonal therapy induces a
                gender-concordant fecal metagenome transition in
                transgender individuals. <em>BMC Medicine</em>,
                <em>22</em>(1), 346. <a
                href="https://doi.org/10.1186/s12916-024-03548-z">https://doi.org/10.1186/s12916-024-03548-z</a>
                </div>
                <div id="ref-mcneil_sun510_2024" class="csl-entry"
                role="listitem">
                McNeil, J. A., Herndon, J., Chang, A. Y., Davidge-Pitts,
                C. J., &amp; Hamidi, O. (2024). <span>SUN-510
                Metabolic</span> effects of masculinizing hormone
                therapy in transgender and gender diverse individuals
                with prior diagnosis of polycystic ovary syndrome.
                <em>Journal of the Endocrine Society</em>, <em>8</em>,
                bvae163.2434. <a
                href="https://doi.org/10.1210/jendso/bvae163.2434">https://doi.org/10.1210/jendso/bvae163.2434</a>
                </div>
                <div id="ref-mettawi_male_2024" class="csl-entry"
                role="listitem">
                Mettawi, A. S. (2024). Male polycystic ovary syndrome
                equivalent. In R. Rehman &amp; A. Sheikh (Eds.),
                <em>Polycystic <span>Ovary Syndrome</span></em> (pp.
                100–110). Elsevier. <a
                href="https://doi.org/10.1016/B978-0-323-87932-3.00022-0">https://doi.org/10.1016/B978-0-323-87932-3.00022-0</a>
                </div>
                <div id="ref-mueller_prevalence_2008" class="csl-entry"
                role="listitem">
                Mueller, A., Gooren, L. J., Naton-Schötz, S., Cupisti,
                S., Beckmann, M. W., &amp; Dittrich, R. (2008).
                Prevalence of <span>Polycystic Ovary Syndrome</span> and
                <span>Hyperandrogenemia</span> in <span
                class="nocase">Female-to-Male Transsexuals</span>.
                <em>The Journal of Clinical Endocrinology &amp;
                Metabolism</em>, <em>93</em>(4), 1408–1411. <a
                href="https://doi.org/10.1210/jc.2007-2808">https://doi.org/10.1210/jc.2007-2808</a>
                </div>
                <div id="ref-nolan_laboratory_2025" class="csl-entry"
                role="listitem">
                Nolan, B. J., &amp; Cheung, A. S. (2025). Laboratory
                <span>Monitoring</span> in <span>Transgender</span> and
                <span>Gender-Diverse Individuals</span>. <em>Clinical
                Chemistry</em>, <em>71</em>(3), 358–377. <a
                href="https://doi.org/10.1093/clinchem/hvaf001">https://doi.org/10.1093/clinchem/hvaf001</a>
                </div>
                <div id="ref-norman_tis_2023" class="csl-entry"
                role="listitem">
                Norman, R. J., Morman, R., &amp; Teede, H. J. (2023).
                <span>“<span>Tis</span> but thy name that is my
                enemy”</span>—the problem with the naming of polycystic
                ovary syndrome. <em>Fertility and Sterility</em>,
                <em>120</em>(2), 249–250. <a
                href="https://doi.org/10.1016/j.fertnstert.2023.03.028">https://doi.org/10.1016/j.fertnstert.2023.03.028</a>
                </div>
                <div id="ref-oguz_prevalence_2023" class="csl-entry"
                role="listitem">
                Oğuz, S. H., Boyraz, B. S., Ertürk, B., &amp; Yıldız, B.
                O. (2023). The prevalence, phenotype and cardiometabolic
                risk of polycystic ovary syndrome in treatment-naïve
                transgender people assigned female at birth.
                <em>Endocrine</em>, <em>84</em>(1), 287–292. <a
                href="https://doi.org/10.1007/s12020-023-03648-5">https://doi.org/10.1007/s12020-023-03648-5</a>
                </div>
                <div id="ref-pfeffer_medical_2023" class="csl-entry"
                role="listitem">
                Pfeffer, C. A., Hines, S., Pearce, R., Riggs, D. W.,
                Ruspini, E., &amp; White, F. R. (2023). Medical
                uncertainty and reproduction of the
                <span>“normal”</span>: <span
                class="nocase">Decision-making</span> around
                testosterone therapy in transgender pregnancy. <em>SSM -
                Qualitative Research in Health</em>, <em>4</em>, 100297.
                <a
                href="https://doi.org/10.1016/j.ssmqr.2023.100297">https://doi.org/10.1016/j.ssmqr.2023.100297</a>
                </div>
                <div id="ref-rangi_prevalence_2024" class="csl-entry"
                role="listitem">
                Rangi, S. K., Rehmer, J., &amp; Ferrando, C. A. (2024).
                Prevalence of <span>Polycystic Ovarian Syndrome</span>
                in <span>Young</span> and <span>Adolescent
                Transmasculine Patients Presenting</span> for
                <span>Gender-Affirming Care</span>. <em>Journal of
                Pediatric and Adolescent Gynecology</em>,
                <em>37</em>(1), 51–55. <a
                href="https://doi.org/10.1016/j.jpag.2023.09.003">https://doi.org/10.1016/j.jpag.2023.09.003</a>
                </div>
                <div id="ref-sendur_influence_2021" class="csl-entry"
                role="listitem">
                Sendur, S. N., &amp; Yildiz, B. O. (2021). Influence of
                ethnicity on different aspects of polycystic ovary
                syndrome: A systematic review. <em>Reproductive
                BioMedicine Online</em>, <em>42</em>(4), 799–818. <a
                href="https://doi.org/10.1016/j.rbmo.2020.12.006">https://doi.org/10.1016/j.rbmo.2020.12.006</a>
                </div>
                <div id="ref-shepherd_genderaffirming_2022"
                class="csl-entry" role="listitem">
                Shepherd, R., Bretherton, I., Pang, K., Mansell, T.,
                Czajko, A., Kim, B., Vlahos, A., Zajac, J. D., Saffery,
                R., Cheung, A., &amp; Novakovic, B. (2022).
                Gender-affirming hormone therapy induces specific
                <span>DNA</span> methylation changes in blood.
                <em>Clinical Epigenetics</em>, <em>14</em>(1), 24. <a
                href="https://doi.org/10.1186/s13148-022-01236-4">https://doi.org/10.1186/s13148-022-01236-4</a>
                </div>
                <div id="ref-streed_assessing_2021" class="csl-entry"
                role="listitem">
                Streed, C. G., Beach, L. B., Caceres, B. A., Dowshen, N.
                L., Moreau, K. L., Mukherjee, M., Poteat, T., Radix, A.,
                Reisner, S. L., &amp; Singh, V. (2021). Assessing and
                <span>Addressing Cardiovascular Health</span> in
                <span>People Who Are Transgender</span> and <span>Gender
                Diverse</span>: <span>A Scientific Statement From</span>
                the <span>American Heart Association</span>.
                <em>Circulation</em>, <em>144</em>(6). <a
                href="https://doi.org/10.1161/CIR.0000000000001003">https://doi.org/10.1161/CIR.0000000000001003</a>
                </div>
                <div id="ref-teede_recommendations_2023"
                class="csl-entry" role="listitem">
                Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A.,
                Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin,
                J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa,
                A., Joham, A. E., the International PCOS Network, Arlt,
                W., Azziz, R., Balen, A., Bedson, L., Berry, L., … Tan,
                K. (2023). Recommendations from the 2023 international
                evidence-based guideline for the assessment and
                management of polycystic ovary syndrome. <em>European
                Journal of Endocrinology</em>, <em>189</em>(2), G43–G64.
                <a
                href="https://doi.org/10.1093/ejendo/lvad096">https://doi.org/10.1093/ejendo/lvad096</a>
                </div>
                <div
                id="ref-therotterdameshre/asrm-sponsoredpcosconsensusworkshopgroup_revised_2004"
                class="csl-entry" role="listitem">
                The Rotterdam PCOS Consensus Workshop Group. (2004).
                Revised 2003 consensus on diagnostic criteria and
                long-term health risks related to polycystic ovary
                syndrome. <em>Fertility and Sterility</em>,
                <em>81</em>(1), 19–25. <a
                href="https://doi.org/10.1016/j.fertnstert.2003.10.004">https://doi.org/10.1016/j.fertnstert.2003.10.004</a>
                </div>
                <div id="ref-thompson_medical_2021" class="csl-entry"
                role="listitem">
                Thompson, J., Hopwood, R. A., deNormand, S., &amp;
                Cavanaugh, T. (2021). Medical <span>Care</span> of
                <span>Trans</span> and <span>Gender Diverse
                Adults</span>. <em>Fenway Health, Boston</em>. <a
                href="https://fenwayhealth.org/wp-content/uploads/Medical-Care-of-Trans-and-Gender-Diverse-Adults-Spring-2021-1.pdf">https://fenwayhealth.org/wp-content/uploads/Medical-Care-of-Trans-and-Gender-Diverse-Adults-Spring-2021-1.pdf</a>
                </div>
                <div id="ref-tienforti_metabolic_2024" class="csl-entry"
                role="listitem">
                Tienforti, D., Castellini, C., Di Giulio, F., Spagnolo,
                L., Muselli, M., Fisher, A. D., Vignozzi, L., Baroni, M.
                G., &amp; Barbonetti, A. (2024). Metabolic
                <span>Features</span> of <span>Assigned Female</span> at
                <span>Birth Transgender People</span> on
                <span>Gender-Affirming Hormone Therapy</span>: <span
                class="nocase">A Meta-analysis</span>. <em>Transgender
                Health</em>, <em>9</em>(6), 466–483. <a
                href="https://doi.org/10.1089/trgh.2023.0040">https://doi.org/10.1089/trgh.2023.0040</a>
                </div>
                <div id="ref-toland_uterine_2024" class="csl-entry"
                role="listitem">
                Toland, M. K., Bonasia, K., Bentz, J., DelBaugh, R. M.,
                Vitale, E. J., Scudder, P. N., &amp; Damiano, E. A.
                (2024). Uterine and <span>Ovarian Histopathology After
                Testosterone</span> for <span>Gender Affirmation</span>:
                <span>A Systematic Review</span>. <em>Transgender
                Health</em>, <em>9</em>(4), 288–297. <a
                href="https://doi.org/10.1089/trgh.2022.0207">https://doi.org/10.1089/trgh.2022.0207</a>
                </div>
                <div id="ref-tordoff_chronic_2025" class="csl-entry"
                role="listitem">
                Tordoff, D. M., Lunn, M. R., Flentje, A., Atashroo, D.,
                Chen, B., Dastur, Z., Lubensky, M. E., Capriotti, M.,
                &amp; Obedin-Maliver, J. (2025). Chronic pelvic pain
                among transgender men and gender diverse adults assigned
                female at birth. <em>Andrology</em>, <em>13</em>(3),
                600–609. <a
                href="https://doi.org/10.1111/andr.13703">https://doi.org/10.1111/andr.13703</a>
                </div>
                <div id="ref-unfer_when_2024" class="csl-entry"
                role="listitem">
                Unfer, V., Kandaraki, E., Pkhaladze, L., Roseff, S.,
                Vazquez-Levin, M. H., Laganà, A. S., Shiao-Yng, C.,
                Yap-Garcia, M. I. M., Greene, N. D. E., Soulage, C. O.,
                Bevilacqua, A., Benvenga, S., Barbaro, D., Pintaudi, B.,
                Wdowiak, A., Aragona, C., Kamenov, Z., Appetecchia, M.,
                Porcaro, G., … Nestler, J. (2024). When one size does
                not fit all: <span>Reconsidering PCOS</span> etiology,
                diagnosis, clinical subgroups, and subgroup-specific
                treatments. <em>Endocrine and Metabolic Science</em>,
                <em>14</em>, 100159. <a
                href="https://doi.org/10.1016/j.endmts.2024.100159">https://doi.org/10.1016/j.endmts.2024.100159</a>
                </div>
                <div id="ref-valentine_multicenter_2021"
                class="csl-entry" role="listitem">
                Valentine, A., Davis, S. M., Dempsey, A., Furniss, A.,
                Juarez-Colunga, E., Pyle, L., Reirden, D., &amp; Nokoff,
                N. (2021). Multicenter <span>Analysis</span> of
                <span>Cardiometabolic-Related Diagnosesin Transgender
                Adolescents</span>. <em>Journal of the Endocrine
                Society</em>, <em>5</em>, A799–A800. <a
                href="https://doi.org/10.1210/jendso/bvab048.1626">https://doi.org/10.1210/jendso/bvab048.1626</a>
                </div>
                <div id="ref-vanhise_racial_2023" class="csl-entry"
                role="listitem">
                VanHise, K., Wang, E. T., Norris, K., Azziz, R.,
                Pisarska, M. D., &amp; Chan, J. L. (2023). Racial and
                ethnic disparities in polycystic ovary syndrome.
                <em>Fertility and Sterility</em>, <em>119</em>(3),
                348–354. <a
                href="https://doi.org/10.1016/j.fertnstert.2023.01.031">https://doi.org/10.1016/j.fertnstert.2023.01.031</a>
                </div>
                <div id="ref-vehmas_somatic_2022" class="csl-entry"
                role="listitem">
                Vehmas, N., Holopainen, E., Suomalainen, L., &amp;
                Savolainen-Peltonen, H. (2022). Somatic
                <span>Health</span> and <span>Psychosocial Background
                Among Finnish Adolescents</span> with <span>Gender
                Dysphoria Seeking Hormonal Interventions</span>.
                <em>Transgender Health</em>, <em>7</em>(6), 505–513. <a
                href="https://doi.org/10.1089/trgh.2021.0084">https://doi.org/10.1089/trgh.2021.0084</a>
                </div>
                <div id="ref-vestering_incidence_2025" class="csl-entry"
                role="listitem">
                Vestering, A., Van Vugt, W. L. J., Berner, A. M.,
                Snijders, M. L. H., Heijer, M. D., Groenman, F. A.,
                Huirne, J. A. F., Wiepjes, C. M., &amp; Van Mello, N. M.
                (2025). Incidence of gynaecological (pre-)malignancies
                and endometrial activity in transmasculine and gender
                diverse individuals using testosterone: A retrospective,
                single-centre cohort study. <em>eClinicalMedicine</em>,
                <em>84</em>, 103248. <a
                href="https://doi.org/10.1016/j.eclinm.2025.103248">https://doi.org/10.1016/j.eclinm.2025.103248</a>
                </div>
                <div id="ref-vujovic_transsexualism_2009"
                class="csl-entry" role="listitem">
                Vujovic, S., Popovic, S., Sbutega-Milosevic, G.,
                Djordjevic, M., &amp; Gooren, L. (2009). Transsexualism
                in <span>Serbia</span>: <span>A Twenty-Year Follow-Up
                Study</span>. <em>The Journal of Sexual Medicine</em>,
                <em>6</em>(4), 1018–1023. <a
                href="https://doi.org/10.1111/j.1743-6109.2008.00799.x">https://doi.org/10.1111/j.1743-6109.2008.00799.x</a>
                </div>
                <div id="ref-witchel_polycystic_2019" class="csl-entry"
                role="listitem">
                Witchel, S. F., Oberfield, S. E., &amp; Peña, A. S.
                (2019). Polycystic <span>Ovary Syndrome</span>:
                <span>Pathophysiology</span>, <span>Presentation</span>,
                and <span>Treatment With Emphasis</span> on
                <span>Adolescent Girls</span>. <em>Journal of the
                Endocrine Society</em>, <em>3</em>(8), 1545–1573. <a
                href="https://doi.org/10.1210/js.2019-00078">https://doi.org/10.1210/js.2019-00078</a>
                </div>
                <div id="ref-wugalter_doubleedged_2024"
                class="csl-entry" role="listitem">
                Wugalter, K., Perovic, M., Karkaby, L., &amp; Einstein,
                G. (2024). The double-edged sword of <span>PCOS</span>
                and gender: Exploring gender-diverse experiences of
                polycystic ovary syndrome. <em>International Journal of
                Transgender Health</em>, <em>25</em>(2), 251–267. <a
                href="https://doi.org/10.1080/26895269.2023.2183448">https://doi.org/10.1080/26895269.2023.2183448</a>
                </div>
                <div id="ref-yaish_functional_2021" class="csl-entry"
                role="listitem">
                Yaish, I., Tordjman, K., Amir, H., Malinger, G.,
                Salemnick, Y., Shefer, G., Serebro, M., Azem, F.,
                Golani, N., Sofer, Y., Stern, N., &amp; Greenman, Y.
                (2021). Functional ovarian reserve in transgender men
                receiving testosterone therapy: Evidence for preserved
                anti-<span>Müllerian</span> hormone and antral follicle
                count under prolonged treatment. <em>Human
                Reproduction</em>, <em>36</em>(10), 2753–2760. <a
                href="https://doi.org/10.1093/humrep/deab169">https://doi.org/10.1093/humrep/deab169</a>
                </div>
                </div>
    </div>
    </div>
</body>
</html>
